SOPHiA GENETICS CFO sells 1,592 shares for taxes

SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,592 Ordinary Shares in an open‑market transaction.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,592 Ordinary Shares in an open‑market transaction. The weighted average sale price was $5.2886 per share. According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on July 2, 2026 and was executed under a pre‑established Rule 10b5‑1(c) trading plan. After this tax‑related sale, Cardoza directly holds 309,092 Ordinary Shares.

Insider Trade Summary 10b5-1

Net Seller: 1,592 shares

Net Sell 1 txn

Insider CARDOZA GEORGE

Role Chief Financial Officer

Sold 1,592 shs ($8K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,592	$5.2886	$8K

Holdings After Transaction: Ordinary Shares — 309,092 shares (Direct)

Footnotes (2)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 1,592 shares Weighted average sale price: $5.2886 per share Post-transaction holdings: 309,092 shares +2 more

5 metrics

Shares sold 1,592 shares Open-market sale on July 6, 2026

Weighted average sale price $5.2886 per share Ordinary Shares sold by CFO

Post-transaction holdings 309,092 shares Ordinary Shares held directly after sale

Price range of sales $4.97–$5.43 per share Multiple transactions within this range

RSU vesting date July 2, 2026 Restricted stock units triggering tax withholding

Key Terms

Rule 10b5-1(c) trading plan, restricted stock units, weighted average price

3 terms

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units on July 2, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPHiA GENETICS (SOPH) disclose for its CFO?

SOPHiA GENETICS disclosed that Chief Financial Officer George Cardoza sold 1,592 Ordinary Shares in an open‑market transaction at a weighted average price of $5.2886 per share. The sale was tied to tax withholding from recently vested restricted stock units.

Why did the SOPHiA GENETICS CFO sell 1,592 shares of SOPH stock?

The CFO sold 1,592 Ordinary Shares to satisfy tax withholding obligations arising from the vesting of restricted stock units on July 2, 2026. The filing states these transactions were not discretionary trades but followed a pre‑established Rule 10b5‑1(c) trading plan.

Was the SOPHiA GENETICS CFO’s SOPH share sale made under a Rule 10b5-1 plan?

Yes. The filing specifies the sales were executed under a pre‑established Rule 10b5‑1(c) trading plan adopted by the CFO. Such plans schedule trades in advance, indicating the timing was pre‑arranged rather than based on real‑time market or company developments.

How many SOPHiA GENETICS (SOPH) shares does the CFO hold after this sale?

After selling 1,592 Ordinary Shares, the CFO directly holds 309,092 Ordinary Shares of SOPHiA GENETICS. This post‑transaction holding figure, disclosed in the filing, helps investors gauge the sale’s scale relative to his remaining ownership stake in the company.

At what prices were the SOPHiA GENETICS CFO’s shares sold in this Form 4 filing?

The reported weighted average sale price was $5.2886 per share. The filing notes that multiple transactions occurred at prices ranging from $4.97 to $5.43, and the reporting person offered to provide detailed breakdowns of shares sold at each individual price upon written request.

Were the SOPHiA GENETICS CFO’s SOPH share sales discretionary trades?

No. The filing explicitly states the sales were to satisfy tax withholding obligations related to restricted stock unit vesting and were executed under a pre‑established Rule 10b5‑1(c) plan, meaning they were not discretionary trades based on current market conditions or new company information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARDOZA GEORGE

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/06/2026		S		1,592(1)	D	$5.2886(2)	309,092	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on July 2, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.43, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)